ArticleVirulence2026
Integrin β3 α2,6-sialylation by the sialyltransferase ST6Gal1 promotes human cytomegalovirus entry into fibroblasts.
Article in Virulence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The interactions between viral ligands and cellular receptors, along with the subsequent entry of Human cytomegalovirus (HCMV) into host cells, represent an important focus of research in virus-host relationships. This study investigated the function and mechanistic role of α2,6-sialylation of Integrin β3 during the early stages of infection in fibroblasts. Analysis of the human Integrin β3 glycomics database revealed that the surface glycans of Integrin β3 are extensively modified with terminal sialic acid residues and occur at relatively high abundance. To evaluate their functional relevance, Integrin β3-knockout cells and α2,6-sialyltransferase ST6Gal1-knockdown cells were established. Quantitative PCR, flow cytometry, and immunofluorescence analyses confirmed that α2,6-sialylation of Integrin β3 is required for viral internalization, and the absence of this modification significantly reduced viral entry into host cells. This observation was further validated through additional virological assays designed to detect viral infection. Mechanistic analysis demonstrated that defective α2,6-sialylation of Integrin β3 impairs the interaction between viral receptors and ligands, preventing activation of the viral entry signaling pathways, Integrin-Src, and resulting in impaired HCMV-induced Rho A-cofilin inactivation. These findings broaden the current understanding of early HCMV infection and highlight ST6Gal1 and Integrin β3 α2,6-sialylation as potential glycobiological targets for therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.